Signia Therapeutics announces it has been selected to present its strategy based on clinical gene expression infection signatures to the upcoming 2nd edition of i4iD “Immunotherapies for Infectious Diseases – host-directed therapies”.
This conference is organized jointly by MabDesign, a French non-profit membership organization in the immunotherapy field, and BIOASTER, a technology institute that leads research programs in four major application fields in health-related microbiology and infectious diseases. The conference will take place in MATMUT Stadium, Lyon, France on December 10thand 11th, 2018.
Presentation will be delivered by Dr Philippe Personne, CEO of Signia Therapeutics, on Monday December 10thin the pitch session “Innovation on HDT Approaches To Treat Infectious Diseases”.
Visit the i4id website https://i4id.org/and Signia Therapeutics website https://signiatherapeutics.com/fr/for detailed information.